Clinical Scorecard: Low-Dose Atropine: Beyond Refraction

At a Glance

Key Highlights

• Low-dose atropine can reduce myopia progression, but efficacy varies by concentration.
• 0.05% atropine generally shows the strongest efficacy among low-dose options.
• Adverse events reported in 35% of children treated with 0.03% atropine.
• Current evidence does not support a universal dosing recommendation.
• 0.01% atropine is a modest option whose effectiveness depends on baseline risk.

Guideline-Based Recommendations

Diagnosis

• Documented progression of at least 0.5 D per year in myopia.

Management

• Consideration of different concentrations of atropine (0.01%, 0.025%, 0.03%, 0.05%) based on individual patient needs.

Monitoring & Follow-up

• Track axial growth and refractive changes over time.

Risks

• Adverse events may occur, leading to treatment discontinuation.

Patient & Prescribing Data

Children aged 3–14 years with myopia between −0.5 D and −6.0 D.

0.01% atropine is often viewed as a safe default but may not sufficiently slow axial elongation.

Clinical Best Practices

• Evaluate individual patient baseline progression and treatment targets before prescribing.
• Utilize trajectory-based endpoints for assessing treatment success.
• Ensure standardized formulations for improved quality control.

Related Resources & Content

• European Medicines Agency
• International Myopia Institute 2025 Report